Phase II trial of GS 6615 in patients with long QT-3 syndrome.

Trial Profile

Phase II trial of GS 6615 in patients with long QT-3 syndrome.

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2014

At a glance

  • Drugs Eleclazine (Primary)
  • Indications Long QT syndrome
  • Focus Pharmacodynamics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 Jul 2014 Planned initiation date changed to 1 Dec 2014, as reported in a Gilead media release.
    • 19 May 2014 This trial is planned to be initiated later in 2014, according to a Gilead Sciences media release.
    • 19 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top